Tauopathies are a diverse category of neurodegenerative disorders distinguished by abnormal tau protein metabolism (tau prions) that ultimately leads to a significant loss of brain cells. The "microtubules" of the cell are stabilized by tau proteins. Misfolding causes intracellular buildup and the development of faulty Neurofibrillary Tangles (NFT), which are no longer able to stabilize the microtubules. Tau proteins are more prevalent in the central nervous system's neurons than they are elsewhere. There are currently no disease-modifying therapies for the treatment of tauopathies. Tauopathies are result of aggregation and precipitation of misfolded tau proteins that normally stabilize neural microtubule. These aggregates form neurofibrillary tangles that lead to neuronal toxicity and degeneration. Neurofibrillary tangles are abnormal cytoplasmic accumulation of tau proteins found in neuronal and glial cells of central nervous system. The term primary tauopathy refers to disorders in which tau protein deposition is the predominant feature. Diseases characterized by tau pathologies considered as having another and diverse driving force are also called secondary tauopathies. Diagnosis is based on neuropathological features, mainly Parkinson’s disease and dementia in later stage. There is a significant clinical overlap between different tauopathies.

Market Dynamics

Increasing launches of new products, and mergers and acquisitions by key market players are expected to drive the global tauopathies treatment market growth. For instance, on July 29, 2020, UCB S.A., a Europe-based global biopharmaceutical company, announced an agreement to enter into a worldwide, exclusive license agreement with F. Hoffmann-La Roche Ltd, a Switzerland-based global pharmaceuticals and diagnostics company, and Genentech, Inc., a U.S.-based biotechnology corporation and a member of the Roche Group, for the global development and commercialization of UCB0107 in Alzheimer’s Disease (AD). UCB0107 is an investigational monoclonal antibody drug being developed by UCB as a potential treatment for patients with tauopathies such as progressive supranuclear palsy (PSP) and Alzheimer’s disease. The transaction remains subject to obtaining antitrust clearance and other customary closing conditions. UCB will provide an exclusive, worldwide license to F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize UCB0107 in Alzheimer’s Disease . In return, UCB S.A  will receive an initial upfront payment of US $120 million.

Key features of the study:

• This report provides an in-depth analysis of the global tauopathies treatment market  and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global tauopathies treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Avanir Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., AB Science, Cortice Biosciences, REGENXBIO Inc., Aquinnah Pharmaceuticals, Neurimmune, Oligomerix, Inc., Biogen, TauRx, Sellas, Selvita S.A, Bristol-Myers Squibb Company, Chronos Therapeutics Limited, and SK Biopharmaceuticals Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global tauopathies treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tauopathies treatment market

Detailed Segmentation:

• Global Tauopathies Treatment Market, By Disease:
  • Frontotemporal Degeneration
    • Pick’s Disease
    • Corticobasal Degeneration (CBD)
    • Progressive Supranuclear Palsy (PSP)
  • Alzheimer’s Disease
  • Other Neurodegenerative Diseases
• Global Tauopathies Treatment Market, By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales
• Global Tauopathies Treatment Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Europe
    
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • North Africa
    • Central Africa
    • South Africa
• Company Profiles
  • Avanir Pharmaceuticals, Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • AB Science
  • Cortice Biosciences
  • REGENXBIO Inc.
  • Aquinnah Pharmaceuticals
  • Neurimmune
  • Oligomerix, Inc.
  • Biogen
  • TauRx
  • Sellas
  • Selvita S.A
  • Bristol-Myers Squibb Company
  • Chronos Therapeutics Limited
  • SK Biopharmaceuticals Co., Ltd.